Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pilot RCT of PIPE-AI for Prediabetes and Diabetes Self-Management
Sponsor: The Hong Kong Polytechnic University
Summary
This pilot randomized controlled trial evaluates the feasibility, effectiveness, and acceptance of the Personalized Interactive Patient Empowerment Artificial Intelligence Platform (PIPE-AI) enhanced by DiabetesGPT among adults with prediabetes or diabetes in Hong Kong primary healthcare settings. Participants will be randomized in a 1:1 ratio to an intervention group receiving PIPE-AI or to a waitlist control group receiving usual care during the first 3 months. Both groups will complete baseline and 3-month assessments, including patient-reported outcome measures, clinical outcomes, healthcare service utilization, and intermittent continuous glucose monitoring using Abbott FreeStyle Libre 2 Plus sensors.
Official title: A Personalized Interactive Patient Empowerment Artificial Intelligence Platform (PIPE-AI) Enhanced by DiabetesGPT in Prediabetes and Diabetes Patients in Primary Healthcare Settings
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2026-08-29
Completion Date
2026-11-29
Last Updated
2026-08-26
Healthy Volunteers
No
Interventions
PIPE-AI digital patient empowerment intervention
PIPE-AI is a personalized interactive patient empowerment artificial intelligence platform enhanced by DiabetesGPT. It integrates individualized risk assessment and a locally fine-tuned large language model to provide personalized health advice, diabetes self-management support, and patient empowerment during the 3-month follow-up period.
Waitlist usual care control
Participants receive usual care during the first 3 months and are given access to the PIPE-AI app after completion of the 3-month follow-up assessment.